Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncimmune Set For Bigger US Push Of Early-Stage Lung Cancer Test

Executive Summary

Oncimmune Ltd. is seeking new distribution partners in the US as it expands commercialization of its a one-of-a-kind immunoassay for early-stage lung cancer that can detect circulating antibodies in the blood of patients with lung cancer up to four years before standard imaging tests. Positive interim data from a UK randomized clinical trial is expected to help fuel uptake of the test.

You may also be interested in...



Market Intel: Can New Wave Of Tests Finally Nail Early Diagnosis Of Lung Cancer?

Early diagnosis of lung cancer continues to be a major clinical challenge and the opportunity for products that can successfully detect the disease early enough to boost survival rate is huge. This article looks into the market potential and highlights companies developing technologies that they believe can finally turn this deadliest of cancers on its head.

QUOTED. Harel Gadot.

Medtech Insight talked with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and market opportunities. See what Gadot said about the market opportunity here. 

Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT035956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel